Sumit Subudhi, MD, PhD
A subset of patients with metastatic castration-resistant prostate cancer (mCRPC) who have low tumor mutational burden (TMB) may benefit from checkpoint inhibition with ipilimumab (Yervoy) if the tumor has a high density of CD8-positive T cells and increased interferon (IFN)-gamma signaling, according to findings from a phase II study published in Science Translational Medicine
“Our findings indicate that anti–CTLA-4 immune checkpoint therapy warrants additional studies in order to develop treatment strategies that may improve survival of patients with metastatic prostate cancer,” Sharma concluded.
- Subudhi SK, Vence L, Zhao H, et al. Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer. Sci Transl Med. 2020;12(537). doi: 1126/scitranslmed.aaz3577
- Immunotherapy effective in metastatic prostate cancers with specific markers of immune activation [news release]. The University of Texas MD Anderson Cancer Center. Published April 1, 2020. https://bit.ly/34aJC6r. Accessed April 2, 2020.
... to read the full story